The previous page is sending you to https://www.businesswire.com/news/home/20210908005271/en/EdiGene-Announces-Clinical-Sites-Activation-and-First-Patient-Enrolled-in-Multicenter-Phase-I-Clinical-Trial-of-its-Investigational-Gene-editing-Hematopoietic-Stem-Cell-Therapy-ET-01-for-Patients-with-Transfusion-Dependent-%CE%B2-thalassemia.

 If you do not want to visit that page, you can return to the previous page.